非劣等性試験の利用方法:医学文献のユーザーガイド
Sohail M Mulla1, Ian A Scott, Cynthia A Jackevicius
1Department of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
JAMA
|December 27, 2012
まとめ
非劣等性試験は,新しい治療法が標準治療法よりも実質的に効果が低いかどうかを評価します. 臨床医は,受け入れ可能なリスクに関する患者の決定が異なるため,効果と利益を考慮する必要があります.
科学分野:
- クリニック・トライアル 臨床試験
- 医学研究方法論 医学研究方法論
背景:
- 効果よりも負担や害の軽減を優先する治療法の使用の増加.
- 非劣等性試験は,新しい治療法が既存の標準よりも実質的に効果が低いことを実証することを目的としています.
研究 の 目的:
- 非劣等性試験における妥当性,解釈,適用性の問題を強調する.
- 新規の治療法に関する情報に基づいた意思決定について,臨床医と患者に知らせる.
主な方法:
- 非劣等性試験の設計と解釈の課題のレビュー.
- 標準治療のサブ最適投与またはランダム化アプローチとしての分析による潜在的なバイアスの議論.
主要な成果:
- 結論は,著者が定義した劣等でない基準に依存し,臨床実践と一致しない場合があります.
- 非劣等設計に適用される標準的な優越性試験方法から,誤解を招く結果が生じることがあります.
結論:
- 臨床医は,新しい治療法の有効性が基準に受け入れられるほど近いかどうかを評価しなければなりません.
- 患者の個々の決定は,効果の潜在的低下に対して利益の交換を伴う.
関連する概念動画
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...

